<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61956">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01754636</url>
  </required_header>
  <id_info>
    <org_study_id>NI 11006</org_study_id>
    <nct_id>NCT01754636</nct_id>
  </id_info>
  <brief_title>Inclusion of Elderly Patients With Colorectal Cancer in Clinical Trials</brief_title>
  <acronym>SAGE</acronym>
  <official_title>Elderly Patients With Colorectal Cancer in Clinical Trials: Factors Associated With Non Inclusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Inadequate representation of elderly cancer patients in randomized clinical
      trials (RCTs) leading to a lack of external validity thereby an uncertainty regarding
      benefit-risk balance of cancer treatment in elderly, especially chemotherapy.

      Hypothesis: The eligibility criteria explain only a part of the under-representation of
      elderly patients in trials. We make the assumptions that 1) Among the eligible, the
      invitation to participate in a trial and inclusion are inversely related to age, 2) Among
      the eligible, there are patients, practitioner, or organization factors that would explain
      the non inclusion of elderly patients.

      Objectives:

        1. To assess, in elderly patients with colorectal cancer, the proportions of patients:

             1. eligible at least to one RCT

             2. invited to participate

             3. included

        2. To identify factors associated with the non-invitation and the non-inclusion in RCT.

      Material and methods:

      Study design: A multicentric prospective cohort survey Population: all patients aged 65
      years or more with a colorectal cancer followed in one of the participating centers.

      Data collection:

        -  At baseline: Patient characteristics (including SOCIO-demographic, oncologic and
           geriatric data) will be collected. Organization factors (e.g. clinical research team)
           will be collected.

        -  Follow-up: the patient will be followed for potential invitation and inclusion in one
           RCT. Reasons of non-invitation or non-inclusion will be assessed.

      Number of subjects needed: 751 Number of centers : 6

      Ethical aspects: each patient will give his oral informed consent. The International Review
      Board of Mondor Hospital (CPP Ile-de-France IX) gave its approval in December 2012.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Inclusion in at least one Randomized controlled Trial</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eligibility to participate in in at least one Randomized controlled Trial</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invitation to participate in in at least one Randomized controlled Trial</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">751</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Elderly patients</arm_group_label>
    <description>65 years old or older, with colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Elderly patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population: all patients aged 65 years or more with a colorectal cancer followed in one of
        the participating centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient aged of 65 years and older

        For a diagnosed colorectal cancer (CRC) irrespective of the stage

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence Canoui-Poitrine, MD, PhD</last_name>
    <phone>(0) 1.49.81.36.95</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.canouï-poitrine@hmn.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia Gregoire</last_name>
    <phone>(0)1 49 81 41 64</phone>
    <phone_ext>+33</phone_ext>
    <email>laetitia.gregoire@hmn.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <state>Val de Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Canoui-poitrine, MD, PhD</last_name>
      <phone>(0) 1.49.81.36.95</phone>
      <phone_ext>+33</phone_ext>
      <email>florence.canouï-poitrine@hmn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laetitia Gregoire</last_name>
      <phone>(0)1 49 81 41 64</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.gregoire@hmn.aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentré F, Soulé JC. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol. 2009 Sep;71(3):249-57. doi: 10.1016/j.critrevonc.2008.11.006. Epub 2009 Jan 7. PubMed PMID: 19131256.</citation>
    <PMID>19131256</PMID>
  </reference>
  <reference>
    <citation>Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003 Apr 1;21(7):1383-9.</citation>
    <PMID>12663731</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal neoplasms</keyword>
  <keyword>Elderly</keyword>
  <keyword>Randomized clinical trials</keyword>
  <keyword>Inclusion.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
